Answers are grounded in this paper and cite their sources.
FGF23 is a bone-derived phosphaturic hormone that may become a useful biomarker for the identification of high-risk patients in chronic but also acute disease. It rises early in chronic kidney disease and is strongly and independently associated with excess morbidity and mortality. Emerging data suggest that FGF23 is also elevated in different scenarios of acute illness. In this review, we give an overview on the role of this interesting disease marker and potential and proven interventional strategies and discuss a blueprint for future research.
No takes yet. Share an insight, caveat, or question.
Schnedl et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: